Anish Desai1, Amishi Desai2, Rose Calixte3, Malaygiri Aparnath4, Alexander Hindenburg2, Steve Salzman4, Joseph P Mathew4. 1. Division of Pulmonary and Critical Care Medicine, Winthrop-University Hospital, 222 Station Plaza North, Suite 400, Mineola, NY, 11501, USA. anish1desai@yahoo.com. 2. Division of Hematology & Oncology, Winthrop-University Hospital, 200, Old Country Road, # 450, Mineola, NY, 11501, USA. 3. Department of Biostatistics, Winthrop-University Hospital, 222, Station Plaza North, Suite 300, Mineola, NY, 11501, USA. 4. Division of Pulmonary and Critical Care Medicine, Winthrop-University Hospital, 222 Station Plaza North, Suite 400, Mineola, NY, 11501, USA.
Abstract
BACKGROUND: Recent studies have demonstrated non-inferiority of rivaroxaban when compared to warfarin for the treatment of pulmonary embolism and deep venous thrombosis. Analysis of data from the EINSTEIN trials has demonstrated that patients who received rivaroxaban had a shorter length of stay (LOS) compared to those who received warfarin. However, these trials had strict inclusion and exclusion criteria, and were designed for a different primary outcome. Also, data from these closely monitored clinical trials may not reflect the daily practice of medicine. OBJECTIVES: To clarify this issue further, we performed a retrospective analysis at our institution, comparing the LOS between patients discharged on rivaroxaban and other conventional anticoagulants (warfarin, enoxaparin, and enoxaparin with warfarin). METHODS: This was a retrospective study of consecutive patients admitted to our institution from January 2011 to July 2014 with newly diagnosed venous thromboembolism (VTE). Inclusion criteria were age > 18 years and objective confirmation of VTE. Exclusion criteria included diagnosis of VTE 24 h after admission, contraindication to anticoagulation, treatment with fibrinolytic agents, patients already on anticoagulation, and pregnancy. Out of 1553 consecutive patients diagnosed with VTE, a total of 414 patients met the eligibility criteria. These patients were further subdivided into four groups based on their discharge anticoagulant: rivaroxaban, warfarin, enoxaparin, and warfarin with enoxaparin. RESULTS: Patients discharged on rivaroxaban had a significantly shorter LOS compared with patients discharged on warfarin (3.5 vs. 7.0 days; p < 0.001), but not when compared to those discharged on enoxaparin alone (3.0 days) or enoxaparin with warfarin (4.0 days) (p > 0.05). The hospital incidence of bleeding and the 6-month readmission rates were not different among the different anticoagulants. CONCLUSIONS: In patients admitted with newly diagnosed VTE, those discharged on rivaroxaban had a significantly shorter LOS compared to those discharged on warfarin. In the appropriate subset of patients with VTE, treatment with rivaroxaban may result in significant cost savings for the hospital.
BACKGROUND: Recent studies have demonstrated non-inferiority of rivaroxaban when compared to warfarin for the treatment of pulmonary embolism and deep venous thrombosis. Analysis of data from the EINSTEIN trials has demonstrated that patients who received rivaroxaban had a shorter length of stay (LOS) compared to those who received warfarin. However, these trials had strict inclusion and exclusion criteria, and were designed for a different primary outcome. Also, data from these closely monitored clinical trials may not reflect the daily practice of medicine. OBJECTIVES: To clarify this issue further, we performed a retrospective analysis at our institution, comparing the LOS between patients discharged on rivaroxaban and other conventional anticoagulants (warfarin, enoxaparin, and enoxaparin with warfarin). METHODS: This was a retrospective study of consecutive patients admitted to our institution from January 2011 to July 2014 with newly diagnosed venous thromboembolism (VTE). Inclusion criteria were age > 18 years and objective confirmation of VTE. Exclusion criteria included diagnosis of VTE 24 h after admission, contraindication to anticoagulation, treatment with fibrinolytic agents, patients already on anticoagulation, and pregnancy. Out of 1553 consecutive patients diagnosed with VTE, a total of 414 patients met the eligibility criteria. These patients were further subdivided into four groups based on their discharge anticoagulant: rivaroxaban, warfarin, enoxaparin, and warfarin with enoxaparin. RESULTS:Patients discharged on rivaroxaban had a significantly shorter LOS compared with patients discharged on warfarin (3.5 vs. 7.0 days; p < 0.001), but not when compared to those discharged on enoxaparin alone (3.0 days) or enoxaparin with warfarin (4.0 days) (p > 0.05). The hospital incidence of bleeding and the 6-month readmission rates were not different among the different anticoagulants. CONCLUSIONS: In patients admitted with newly diagnosed VTE, those discharged on rivaroxaban had a significantly shorter LOS compared to those discharged on warfarin. In the appropriate subset of patients with VTE, treatment with rivaroxaban may result in significant cost savings for the hospital.
Entities:
Keywords:
Length of stay; Rivaroxaban; Venous thromboembolism; Warfarin
Authors: Brahim K Bookhart; Lloyd Haskell; Luke Bamber; Maria Wang; Jeff Schein; Samir H Mody Journal: J Med Econ Date: 2014-08-04 Impact factor: 2.448
Authors: Giancarlo Agnelli; Harry R Buller; Alexander Cohen; Madelyn Curto; Alexander S Gallus; Margot Johnson; Urszula Masiukiewicz; Raphael Pak; John Thompson; Gary E Raskob; Jeffrey I Weitz Journal: N Engl J Med Date: 2013-07-01 Impact factor: 91.245
Authors: Frederick A Spencer; Cathy Emery; Darleen Lessard; Frederick Anderson; Sri Emani; Jayashri Aragam; Richard C Becker; Robert J Goldberg Journal: J Gen Intern Med Date: 2006-07 Impact factor: 5.128
Authors: Bonno van Bellen; Luke Bamber; Francine Correa de Carvalho; Martin Prins; Maria Wang; Anthonie W A Lensing Journal: Curr Med Res Opin Date: 2014-01-22 Impact factor: 2.580
Authors: Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong Journal: N Engl J Med Date: 2010-12-03 Impact factor: 91.245
Authors: Catherine J Mercaldi; Mike Ciarametaro; Beth Hahn; George Chalissery; Matthew W Reynolds; Stephen D Sander; Gregory P Samsa; David B Matchar Journal: Stroke Date: 2010-12-09 Impact factor: 7.914
Authors: Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber Journal: N Engl J Med Date: 2009-12-10 Impact factor: 91.245
Authors: Luke Bamber; Maria Y Wang; Martin H Prins; Cathleen Ciniglio; Rupert Bauersachs; Anthonie W A Lensing; Stefan J Cano Journal: Thromb Haemost Date: 2013-07-11 Impact factor: 5.249
Authors: Jeffrey Trocio; Virginia M Rosen; Anu Gupta; Oluwaseyi Dina; Lien Vo; Patrick Hlavacek; Lisa Rosenblatt Journal: Clinicoecon Outcomes Res Date: 2018-12-19
Authors: Sylvia Haas; Lorenzo G Mantovani; Reinhold Kreutz; Danja Monje; Jonas Schneider; Elizabeth R Zell; Miriam Tamm; Martin Gebel; Jörg-Peter Bugge; Walter Ageno; Alexander G G Turpie Journal: Res Pract Thromb Haemost Date: 2021-03-20